Off-label or off-limits?

被引：0
作者：
Mark Ratner
Trisha Gura
机构：
[1] Trisha Gura is a Boston-based writer and former Knight fellow.,
来源：
Nature Biotechnology | 2008年 / 26卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Off-label prescribing is a fundamental fact of life of healthcare systems, but the promotion of off-label uses by drug sponsors is a fundamental sin. Regulators, legislators and drug makers are wrestling to find the right balance.
引用
收藏
页码：867 / 875
页数：8
相关论文
共 9 条
[1]  
Radley DC(2006)undefined Arch. Intern. Med. 166 1021-1026
[2]  
Casali PG(2007)undefined Ann. Oncol. 18 1923-1925
[3]  
Conroy S(2003)undefined Ann. Oncol. 14 42-47
[4]  
Newman C(2003)undefined Ann. Oncol. 14 1-5
[5]  
Gudka S(1983)undefined N. Engl. J. Med. 308 1457-1463
[6]  
Boos J(1992)undefined N. Engl. J. Med. 327 168-173
[7]  
Avorn J(undefined)undefined undefined undefined undefined-undefined
[8]  
Soumerai SB(undefined)undefined undefined undefined undefined-undefined
[9]  
Avorn J(undefined)undefined undefined undefined undefined-undefined
1